For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue from customers | - | - | 0 | - |
| Research and development | 2,280 | 1,120 | 3,702 | 2,735 |
| General and administrative | 4,715 | 5,674 | 3,826 | 2,268 |
| Total operating expenses | 6,995 | 6,794 | 7,528 | 5,003 |
| Loss from operations | -6,995 | -6,794 | -7,528 | -5,003 |
| Warrant issuance costs | - | - | -258* | 129 |
| Interest income | - | - | 2 | 4 |
| Change in fair value of convertible rights | - | - | -75* | - |
| Change in fair value of warrant liabilities | - | - | 25,367* | -1,824 |
| Gain on extinguishment | - | - | 1,510* | -994 |
| R&d tax incentive | 482 | 389 | -432 | 421 |
| Foreign exchange losss/(gaines) | -24 | -13 | 1 | 41 |
| Interest income | -5 | -5 | -151* | 132 |
| Eloc commitment fee | - | - | -274* | - |
| Share of earnings (loss) of joint venture | 11 | 6 | - | - |
| Total other income, net | 474 | 387 | -24,075 | 1,035 |
| Loss before income tax expense | -6,521 | -6,407 | -31,603 | -3,968 |
| Net loss | -6,521 | -6,407 | -31,603 | -3,968 |
| Currency translation adjustment, net of tax | -287 | 223 | 371 | -88 |
| Total comprehensive loss | -6,808 | -6,184 | -31,232 | -4,056 |
| Basic EPS | -0.02 | -0.02 | -0.377 | -0.2 |
| Diluted EPS | -0.02 | -0.02 | -0.377 | -0.2 |
| Basic Average Shares | 349,464,317 | 310,309,659 | 82,917,283 | 19,632,539 |
| Diluted Average Shares | 349,464,317 | 310,309,659 | 82,917,283 | 19,632,539 |
Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL)